Abbott Laboratories $ABT Shares Bought by Jensen Investment Management Inc.

Jensen Investment Management Inc. lifted its holdings in Abbott Laboratories (NYSE:ABT) by 74.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,378,563 shares of the healthcare product maker’s stock after buying an additional 1,012,778 shares during the quarter. Abbott Laboratories comprises 3.8% of Jensen Investment Management Inc.’s portfolio, making the stock its 10th biggest holding. Jensen Investment Management Inc.’s holdings in Abbott Laboratories were worth $323,508,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. St. Louis Trust Co boosted its position in Abbott Laboratories by 21.7% in the 1st quarter. St. Louis Trust Co now owns 9,679 shares of the healthcare product maker’s stock valued at $1,284,000 after buying an additional 1,723 shares during the last quarter. Csenge Advisory Group increased its stake in shares of Abbott Laboratories by 21.0% in the 1st quarter. Csenge Advisory Group now owns 19,307 shares of the healthcare product maker’s stock valued at $2,529,000 after buying an additional 3,356 shares during the period. Brogan Financial Inc. raised its position in shares of Abbott Laboratories by 7.3% during the first quarter. Brogan Financial Inc. now owns 3,215 shares of the healthcare product maker’s stock worth $426,000 after acquiring an additional 218 shares during the last quarter. Finally, SNS Financial Group LLC lifted its stake in shares of Abbott Laboratories by 0.7% during the first quarter. SNS Financial Group LLC now owns 12,591 shares of the healthcare product maker’s stock valued at $1,670,000 after acquiring an additional 83 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Raymond James Financial lifted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Evercore ISI lowered their price target on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating for the company in a research report on Wednesday, October 15th. Weiss Ratings restated a “buy (b)” rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Mizuho lifted their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $147.00 price target on shares of Abbott Laboratories in a research note on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $147.00.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $130.59 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The firm has a fifty day moving average of $130.38 and a 200-day moving average of $131.35. The firm has a market capitalization of $227.08 billion, a price-to-earnings ratio of 16.36, a price-to-earnings-growth ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter last year, the business posted $1.21 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is currently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.